Aditxt, Inc., a biotech company, has announced the offering of 188,000 shares of common stock and pre-funded warrants to purchase up to 942,189 shares of common stock. The pre-funded warrants are immediately exercisable at a nominal price of $0.001 per share and may be exercised at any time until fully exercised. The offering is filed under Rule 424(b)(5) with the SEC, and the common stock is traded on The Nasdaq Capital Market under the symbol 'ADTX.' The offering aims to raise capital for general corporate purposes, including research and development, and working capital. The last reported sale price of Aditxt's common stock on The Nasdaq Capital Market as of August 8, 2024, was $1.25 per share. The company has engaged H.C. Wainwright & Co., LLC as the exclusive placement agent for the offering. The placement agent will receive a cash fee, management fee, and reimbursement for certain expenses, as well as warrants to purchase shares of common stock. The offering is expected to close on or about August 9, 2024, subject to customary closing conditions.

Aditxt, Inc., a biotech company, has announced the offering of 188,000 shares of common stock and pre-funded warrants to purchase up to 942,189 shares of common stock. The pre-funded warrants are immediately exercisable at a nominal price of $0.001 per share and may be exercised at any time until fully exercised. The offering is filed under Rule 424(b)(5) with the SEC, and the common stock is traded on The Nasdaq Capital Market under the symbol 'ADTX.' The offering aims to raise capital for general corporate purposes, including research and development, and working capital. The last reported sale price of Aditxt's common stock on The Nasdaq Capital Market as of August 8, 2024, was $1.25 per share. The company has engaged H.C. Wainwright & Co., LLC as the exclusive placement agent for the offering. The placement agent will receive a cash fee, management fee, and reimbursement for certain expenses, as well as warrants to purchase shares of common stock. The offering is expected to close on or about August 9, 2024, subject to customary closing conditions.